MedTrace Logo

Pilot Study- Treat to Target Vitamin D in End Stage Renal Disease

NCT04167111 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2024-09-03

No results posted yet for this study

Summary

Feasibility of dose adjustment to reach a 6 month 25-hydroxy vitamin D level of 35-50 ng/ml in end stage renal disease patients

Conditions

  • Chronic Kidney Diseases

Interventions

DIETARY_SUPPLEMENT

Cholecalciferol

Vitamin D

Sponsors & Collaborators

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Laura Graeff-Armas, MD, MS, PhD · University of Nebraska

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-06
Primary Completion
2021-05-06
Completion
2021-05-06

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04167111 on ClinicalTrials.gov